Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes ...

Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) has been available in China for diabetes since 2021, and the Wegovy formulation ... Shares in Eli Lilly rose sharply in pre-market trading ...

Novo Nordisk has had its NDA for an oral formulation of Wegovy accepted by the FDA. It would be the first obesity-targeted GLP-1 in pill form. Shares in Eli Lilly have weakened after pharmacy ...